Podcasts

E-Books

Videos

Articles

Business & Practice

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Opening the door to biosimilar competition starts with breaking down the patent barrier, says Christine Simmon, JD.

Christine Simmon and the Fight for Patent Reform

Now that Polpharma Biologics has fully integrated Bioceros into its brand, the company hopes to become one of the world’s leading biologics manufacturers.

Polpharma Biologics: The Polish Biosimilar Powerhouse

Tony Hagen is senior managing editor for The Center for Biosimilars

United States Pharmacopeia (USP), the FDA, and others deliver constructive critique on how India can bolster quality in its biopharmaceutical industry.

USP Panel Recommends Quality Upgrade for India's Biopharmaceutical Industry

Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.

Samsung Bioepis Enters Breast and Gastric Market in Brazil

Nancy J. Globus, PharmD, is Vice President of Regulatory Affairs for the Accreditation Council for Medical Affairs, based in Oradell, New Jersey. Nancy focuses on helping the industry build error prevention into products by evaluating proposed names and labels prior to regulatory approval. In her 20-year medication safety career, she has reviewed thousands of names for submission to FDA, European Medicines Agency, and Health Canada. In addition to medication safety, she is passionate about patient advocacy and community pharmacy. You can find her at www.medicalaffairsspecialist.org/approve or on Twitter @MedSafetyGal.

Alphabet Soup: The Story Behind Biosimilar Nonproprietary Name Suffixes

With a sizable milestone payment from its partner Mylan, Revance has stepped up efforts to launch contenders in the Botox space.

Revance Moves Forward With 2 Botox Competitors

Originator biologics should be monitored as closely as biosimilars, according to Gary Lyman, MD, MPH, of the Hutchinson Institute for Cancer Outcomes Research.

Lyman Reassures on Biosimilar Quality

In an award-winning attempt to get closer to patients, Samsung Bioepis has replaced harsh typography with white backgrounds and gentle shapes on its new biosimilar packaging.
 

Samsung Bioepis Appeals to Patients Through Package Design

Teva Pharmaceutical Industries has expanded on its hopes for a biosimilar comeback with a commercialization deal with Alvotech, which could bring as many as 5 biosimilars to the US market.

Teva, Alvotech Partner on Biosimilars for US Market

Biosimilar exports make up a hefty chunk of biologics and other drug exports from the Republic of Korea to the United States and Europe, according to a report.

Business